Key result
After age adjustment, 10-year all-cause mortality after percutaneous coronary intervention for drug-eluting in-stent restenosis did not differ significantly between female and male patients (adjusted HR 0.96).
Why the study?
Limited data were available regarding sex-related long-term outcomes of patients treated for coronary drug-eluting stent restenosis.
Do sex-related differences exist in long-term outcomes after percutaneous coronary intervention for drug-eluting stent restenosis?
Cohort (n=3,511)
Yes
Do sex-related differences exist in long-term outcomes after percutaneous coronary intervention for drug-eluting stent restenosis?
Hazard Ratio: 0.96 (95% CI 0.83–1.11)
Absolute Event Rate: 54.7% vs 46%
p-value: p=0.6
In patients undergoing percutaneous coronary intervention for drug-eluting stent in-stent restenosis, long-term age-adjusted mortality is similar between sexes, but women have a significantly lower risk of repeat revascularization.
Limited data are available for sex-related long-term outcomes of patients treated for coronary drug-eluting stent (DES) restenosis. The aim of this observational, retrospective analysis was to close this lack of evidence. Between January 2007 and February 2021, a total of 3511 patients with 5497 in-stent restenosis (ISR) lesions were treated at two large-volume centers in Munich, Germany, of which 763 (21.7%) were female. Endpoints of interest were all-cause mortality and rates of repeat revascularization. Outcomes are presented as Kaplan-Meier event rates. Univariate and multivariate analyses were performed. Female patients were older (72.1 ± 10.4 versus 68.4 ± 10.4 years, p < 0.001) and suffered more often from diabetes (38.8% versus 34.4%, p = 0.029). There was no statistical difference regarding the clinical presentation and interventional treatment strategy. After 10 years, the risk of all-cause mortality was higher in female patients [hazard ratio (HR) 1.18 (1.02-1.35); p = 0.022]; however, after adjustment for age, the risk did not differ significantly between both sexes [adjusted HR 0.96 (0.83-1.11); p = 0.6]. Regarding target vessel revascularization (TVR) and non-target vessel revascularization (NTVR), the risk was lower in female patients [HR 0.73 (0.61-0.87); p < 0.001 and HR 0.74 (0.64-0.86); p < 0.001] even after age adjustment. No statistical differences were found regarding the risk of target lesion revascularization, target vessel myocardial infarction and stent thrombosis. In the long term, all-cause mortality after percutaneous coronary intervention of DES-ISR did not differ between both sexes after age adjustment. The risk of TVR and NTVR was lower in female patients even after age adjustment.
No takes yet. Share an insight, caveat, or question.
Kuna et al. (2025) conducted a cohort in Drug-eluting stent in-stent restenosis (n=3,511). Female sex vs. Male sex was evaluated on All-cause mortality at 10 years (age-adjusted) (adjusted HR 0.96, 95% CI 0.83-1.11, p=0.6). After age adjustment, 10-year all-cause mortality after percutaneous coronary intervention for drug-eluting in-stent restenosis did not differ significantly between female and male patients (adjusted HR 0.96).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: